Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

VaxGen Sells Vaccine Program

May 12, 2008 | A version of this story appeared in Volume 86, Issue 19

South San Francisco-based VaxGen has sold its anthrax vaccine program to Rockville, Md.-based Emergent BioSolutions. For $2 million up front and another possible $8 million in milestone payments, Emergent gets all rights and assets related to a recombinant protective antigen (rPA) vaccine. VaxGen will also receive a percentage of any future sales revenue. Emergent hopes the vaccine, which has undergone a Phase II clinical trial, will be a candidate for the U.S. government's 25 million-dose rPA anthrax vaccine stockpile. The company already has a $448 million contract to deliver 18.75 million doses of its BioThrax vaccine, the only FDA-approved vaccine for preventing anthrax infection.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.